Research programme: antibacterials - Destiny Pharma

Drug Profile

Research programme: antibacterials - Destiny Pharma

Alternative Names: DPD201; DPD202; DPD204; DPD206; DPD207; DPD241; MQ drug series - Destiny Pharma; XF drug series - Destiny Pharma; XF-42; XF-70

Latest Information Update: 16 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Destiny Pharma
  • Class Metalloporphyrins; Porphyrins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 28 Mar 2012 Preclinical trials in Bacterial infections in United Kingdom (Inhalation)
  • 28 Oct 2008 Preclinical pharmacodynamics data in Bacterial infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
  • 25 Jan 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top